An overview of insulin glargine

被引:16
作者
Home, PD [1 ]
Ashwell, SG [1 ]
机构
[1] Newcastle Univ, Sch Med, Dept Diabet & Metab, Newcastle Upon Tyne NE2 4HH, Tyne & Wear, England
关键词
basal insulin; diabetes; hypoglycaemia; insulin glargine; NPH insulin;
D O I
10.1002/dmrr.317
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Insulin glargine is an innovative, long-acting human insulin analogue, whose prolonged mean activity profile has no pronounced peak. Accordingly, it mimics more closely the natural physiological profile of basal endogenous insulin secretion than do traditional extended-acting insulins such as NPH insulin. As would be expected for a more satisfactory basal insulin, clinical trials comparing insulin glargine with NPH insulin show less nocturnal hypoglycaemia, improved pre-breakfast blood glucose levels, or both. no substantive safety concerns have emerged for insulin Furthermore, insulin glargine represents the first major advance in the glargine. Thus, insulin glargine represents the first major advance in the provision of basal insulin injection therapy for people with type 1 and type 2 diabetes for over 50 years. Copyright (C) 2002 John Wiley Sons, Ltd.
引用
收藏
页码:S57 / S63
页数:7
相关论文
共 33 条
[1]   Optimal provision of daytime NPH insulin in patients using the insulin analog lispro [J].
Ahmed, ABE ;
Home, PD .
DIABETES CARE, 1998, 21 (10) :1707-1713
[2]   Growth promoting and metabolic activity of the human insulin analogue [Gly(A21),Arg(B31),Arg(B32)]insulin (HOE 901) in muscle cells [J].
Bahr, M ;
Kolter, T ;
Seipke, G ;
Eckel, J .
EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 320 (2-3) :259-265
[3]   The long acting human insulin analog HOE 901:: Characteristics of insulin signalling in comparison to Asp(B10) and regular insulin [J].
Berti, L ;
Kellerer, M ;
Bossenmaier, B ;
Seffer, E ;
Seipke, G ;
Häring, HU .
HORMONE AND METABOLIC RESEARCH, 1998, 30 (03) :123-129
[4]   Insulin glargine [J].
Bolli, GB ;
Owens, DR .
LANCET, 2000, 356 (9228) :443-445
[5]  
Cryer PE, 1999, DIABETES-METAB RES, V15, P42, DOI 10.1002/(SICI)1520-7560(199901/02)15:1<42::AID-DMRR1>3.0.CO
[6]  
2-B
[7]   THE STRUCTURAL BASIS OF INSULIN AND INSULIN-LIKE GROWTH-FACTOR-I RECEPTOR-BINDING AND NEGATIVE COOPERATIVITY, AND ITS RELEVANCE TO MITOGENIC VERSUS METABOLIC SIGNALING [J].
DEMEYTS, P .
DIABETOLOGIA, 1994, 37 :S135-S148
[8]  
DREYER M, 1994, DIABETOLOGIA, V37, pA78
[9]  
Forjanic-Klapproth J, 2001, DIABETOLOGIA, V44, pA287
[10]  
Francis A J, 1985, Diabet Med, V2, P89